|
Authored by:
- Central Florida Division External Communications
|
Estimated read time: 1 minute
Choose the health content that's right for you, and get it delivered right in your inbox
Patients with severe cases of COVID-19 may find help in an unlikely source – the blood plasma of patients who’ve recovered from the disease.
It’s called convalescent plasma, and the idea is that antibodies in the donated plasma will help fight the disease in patients who are suffering through it.
“This is an extremely exciting development that shows promise in helping our sickest patients,” said Dr. Juliana Gaitan, who is leading the project. “We’re among the first hospitals in the country to begin offering this therapy.”
The U.S. Food & Drug Administration is facilitating access to the COVID-19 convalescent plasma for use in patients with serious or immediately life-threatening infections.
AdventHealth is working with OneBlood to solicit donations from recovered patients across the region. OneBlood will collect the plasma, which can be collected either from whole-blood or plasma-only donors.
Recovered patients who are at least 15 days out from experiencing symptoms are eligible to donate.
“We are really depending on the community for support,” said Dr. Gaitan. “As the number of COVID-19 cases increases, we expect high demand for this potentially lifesaving treatment.”
Prospective donors can get more information here:
https://www.oneblood.org/lp/covid-19-convalescent-plasma.stml#btndonate
Recent News
-
Our Communities
From serving meals to installing gardens and everything in between, AdventHealth team members volunteered nearly 2,500 hours to serve wherever the needs were the greatest.
-
Our Communities
The FLAME study represents a first-of-its-kind study of the long-term adherence to and effects of an exercise intervention on brain health, cognition and Alzheimer's disease pathology.
-
Our Communities
Physicians and scientists discuss research designed to explore the mystifying effects of exercise, from aging well to influencing cancer, and why people respond differently.